Pernille Rudebeck Mogensen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Pernille Rudebeck Mogensen has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
- Thomas Leth Frandsen
Mary Elizabeth’s Hospital and Juliane Marie Centre, Copenhagen University Hospital – Rigshospitalet, Copenhagen, Denmark
4 shared publications Kathrine Grell
Department of Pediatrics and Adolescent Medicine, University Hospital Rigshospitalet, Copenhagen, Denmark
2 shared publications- Kjeld Schmiegelow
Department of Pediatrics and Adolescent Medicine, Copenhagen University Hospital, Copenhagen, Denmark
2 shared publications Mats Heyman
Department of Women’s and Children’s Health Karolinska Institutet Stockholm Sweden
2 shared publicationsAllan Vaag
Steno Diabetes Center Copenhagen, Copenhagen, Denmark
1 shared publicationAnders Forslund
Department of Women's and Children's Health Uppsala University Uppsala Sweden
1 shared publication
Latest Publications
- Open Access
- 31 July 2025
- Published by SAGE Publications in Diabetes Technology & Therapeutics
- Vol. 28 (1) , 47-54
Impact of an Insulin Bolus Calculator on Glycemic Control in Relation to Exercise—A Crossover Randomized Controlled Trial
Introduction: Exercise benefits individuals with type 1 diabetes (T1D) but is often hindered by the risk of hypoglycemia. While guidelines provide strategies to mitigate this risk, adherence to recommendations on exercise remains low. Bolus calculators, such as Hedia Diabetes Assistant (HDA), offer a potential way to address this challenge by integrating exercise-related insulin adjustments into daily routines. This trial evaluates the safety and efficacy of HDA in improving glycemic control during exercise. Methods: This randomized, controlled crossover pilot study included 20 adults diagnosed with T1D for >1 year using multiple daily insulin injections and HbA1c between 42 and 72 mmol/mol (6.0–8.6%). Participants were randomized to first use either HDA (arm A) or their habitual diabetes management (arm B) before and after performing a 45-min moderate-intensity session on an exercise bike and subsequently crossover. The primary outcome was change in time in range (TIR) over the two 24 h periods. Results: The mean differences (95% confidence interval [CI]) in TIR and time above range (>10.0 mmol/L) were −2.3% (−13.1%, 8.5%) and 3.93% (−5.7%, 13.5%), respectively, and the median difference in time below range (<3.9 mmol/L) was −0.87% (−2.8%, 0.5%). The incidence rate ratio (95% CI) for total hypoglycemic episodes using HDA was −0.56 (−1.41, 0.29). Safety outcomes revealed fewer adverse events when using HDA. Conclusion: The HDA insulin bolus calculator with an integrated exercise feature appears safe to use when compared with habitual insulin management in people with T1D during moderate-intensity exercise.
- 31 July 2025
- Published by SAGE Publications in Diabetes Technology & Therapeutics
- Vol. 28 (1) , 47-54
Open AccessImpact of an Insulin Bolus Calculator on Glycemic Control in Relation to Exercise—A Crossover Randomized Controlled Trial
Introduction: Exercise benefits individuals with type 1 diabetes (T1D) but is often hindered by the risk of hypoglycemia. While guidelines provide strategies to mitigate this risk, adherence to recommendations on exercise remains low. Bolus calculators, such as Hedia Diabetes Assistant (HDA), offer a potential way to address this challenge by integrating exercise-related insulin adjustments into daily routines. This trial evaluates the safety and efficacy of HDA in improving glycemic control during exercise. Methods: This randomized, controlled crossover pilot study included 20 adults diagnosed with T1D for >1 year using multiple daily insulin injections and HbA1c between 42 and 72 mmol/mol (6.0–8.6%). Participants were randomized to first use either HDA (arm A) or their habitual diabetes management (arm B) before and after performing a 45-min moderate-intensity session on an exercise bike and subsequently crossover. The primary outcome was change in time in range (TIR) over the two 24 h periods. Results: The mean differences (95% confidence interval [CI]) in TIR and time above range (>10.0 mmol/L) were −2.3% (−13.1%, 8.5%) and 3.93% (−5.7%, 13.5%), respectively, and the median difference in time below range (<3.9 mmol/L) was −0.87% (−2.8%, 0.5%). The incidence rate ratio (95% CI) for total hypoglycemic episodes using HDA was −0.56 (−1.41, 0.29). Safety outcomes revealed fewer adverse events when using HDA. Conclusion: The HDA insulin bolus calculator with an integrated exercise feature appears safe to use when compared with habitual insulin management in people with T1D during moderate-intensity exercise.
- Open Access
- 10 September 2020
- Published by Wiley in European Journal of Haematology
- Vol. 105 (6) , 797-807
Impact of body mass index on relapse in children with acute lymphoblastic leukemia treated according to Nordic treatment protocols
Objectives: High body mass index (BMI) is associated with poorer survival in childhood acute lymphoblastic leukemia (ALL), but the actual impact on the risk of relapse still needs to be clarified. We evaluated the impact of BMI at diagnosis on the risk of relapse in children with ALL treated according to Nordic Society of Paediatric Haematology and Oncology (NOPHO) protocols.Method: In a multicenter study, we collected data on BMI at diagnosis and outcome of 2558 children aged 2.0‐17.9 years diagnosed between 1992 and 2016. Patients were divided into four groups according to International Obesity Task Force (IOTF) childhood BMI cut‐offs: underweight, 2.Results: In Cox multivariate regression analyses, an increased risk of relapse was observed in children aged 10‐17.9 years with unhealthy BMI at diagnosis (underweight hazard ratio HR: 2.90 [95% confidence interval: 1.24‐6.78], P = .01; overweight, HR: 1.95 [1.11‐3.43], P = .02, and obese HR: 4.32 [95% 2.08‐8.97], P < .001), compared to children with healthy weight. BMI had no impact on relapse in children under 10 years of age.Conclusion: High BMI, and especially obesity at diagnosis, is an independent adverse prognostic factor for relapse in older children with ALL.
- 10 September 2020
- Published by Wiley in European Journal of Haematology
- Vol. 105 (6) , 797-807
Open AccessImpact of body mass index on relapse in children with acute lymphoblastic leukemia treated according to Nordic treatment protocols
Objectives: High body mass index (BMI) is associated with poorer survival in childhood acute lymphoblastic leukemia (ALL), but the actual impact on the risk of relapse still needs to be clarified. We evaluated the impact of BMI at diagnosis on the risk of relapse in children with ALL treated according to Nordic Society of Paediatric Haematology and Oncology (NOPHO) protocols.Method: In a multicenter study, we collected data on BMI at diagnosis and outcome of 2558 children aged 2.0‐17.9 years diagnosed between 1992 and 2016. Patients were divided into four groups according to International Obesity Task Force (IOTF) childhood BMI cut‐offs: underweight, 2.Results: In Cox multivariate regression analyses, an increased risk of relapse was observed in children aged 10‐17.9 years with unhealthy BMI at diagnosis (underweight hazard ratio HR: 2.90 [95% confidence interval: 1.24‐6.78], P = .01; overweight, HR: 1.95 [1.11‐3.43], P = .02, and obese HR: 4.32 [95% 2.08‐8.97], P < .001), compared to children with healthy weight. BMI had no impact on relapse in children under 10 years of age.Conclusion: High BMI, and especially obesity at diagnosis, is an independent adverse prognostic factor for relapse in older children with ALL.
- 13 August 2020
- Published by Taylor & Francis in Nutrition and Cancer
- Vol. 73 (9) , 1816-1820
Effect of Fish Oil Supplementation on Hyperlipidemia during Childhood Acute Lymphoblastic Leukemia Treatment – A Pilot Study
Hyperlipidemia is common during contemporary treatment of childhood acute lymphoblastic leukemia and may increase risk of osteonecrosis, thrombosis, and possibly acute pancreatitis. Marine fatty acids found in fish oil decrease levels of triglycerides and possibly total cholesterol in hyperlipidemic patients. This prospective pilot study provided fish oil for 83 days to seven children undergoing acute lymphoblastic leukemia treatment. On average fish oil was consumed 74% of the intervention period. Further, we found significant lower levels of triglycerides (P = 0.016) and total cholesterol (P = 0.027) compared to 22 historical controls, although correction for one extra PEG-asparaginase dose reduced the level of significance. However, the findings indicate that fish oil may alleviate development of hyperlipidemia during acute lymphoblastic leukemia treatment. Randomized controlled trials are warranted to confirm these findings and to investigate the potential effect of fish oil supplements on development of severe adverse events, including osteonecrosis, thrombosis, and acute pancreatitis.
- 13 August 2020
- Published by Taylor & Francis in Nutrition and Cancer
- Vol. 73 (9) , 1816-1820
Effect of Fish Oil Supplementation on Hyperlipidemia during Childhood Acute Lymphoblastic Leukemia Treatment – A Pilot Study
Hyperlipidemia is common during contemporary treatment of childhood acute lymphoblastic leukemia and may increase risk of osteonecrosis, thrombosis, and possibly acute pancreatitis. Marine fatty acids found in fish oil decrease levels of triglycerides and possibly total cholesterol in hyperlipidemic patients. This prospective pilot study provided fish oil for 83 days to seven children undergoing acute lymphoblastic leukemia treatment. On average fish oil was consumed 74% of the intervention period. Further, we found significant lower levels of triglycerides (P = 0.016) and total cholesterol (P = 0.027) compared to 22 historical controls, although correction for one extra PEG-asparaginase dose reduced the level of significance. However, the findings indicate that fish oil may alleviate development of hyperlipidemia during acute lymphoblastic leukemia treatment. Randomized controlled trials are warranted to confirm these findings and to investigate the potential effect of fish oil supplements on development of severe adverse events, including osteonecrosis, thrombosis, and acute pancreatitis.
- Open Access
- 6 April 2020
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 15 (4) , e0231209
Dyslipidemia at diagnosis of childhood acute lymphoblastic leukemia
As survival of acute lymphoblastic leukemia (ALL) exceeds 90%, limiting therapy-related toxicity has become a key challenge. Cardio-metabolic dysfunction is a challenge during and after childhood ALL therapy. In a single center study, we measured triglycerides (TG), total cholesterol (TC), high (HDL) and low density lipoproteins (LDL) levels at diagnosis and assessed the association with BMI, early therapy response, on-therapy hyperlipidemia and the toxicities; thromboembolism, osteonecrosis and pancreatitis. We included 127 children (1.0–17.9 years) all treated according to the NOPHO ALL2008 protocol. Dyslipidemia was identified at ALL-diagnosis in 99% of the patients, dominated by reduced HDL levels (98%) and mild hypertriglyceridemia (61%). Hypertriglyceridemia was not associated with body mass index (P = 0.71). Five percent of patients had mild hypercholesterolemia, 14% had mild hypocholesterolemia, 13% had decreased and 1% elevated LDL-levels. Increased TG and TC levels at ALL-diagnosis were not associated with any on-therapy lipid levels. Lipid levels and BMI were not associated to MRD after induction therapy; However, BMI and hypercholesterolemia were associated with worse risk group stratification (P<0.045 for all). The cumulative incidence of thromboembolism was increased both for patients with hypo- (20.0%) and hypercholesterolemia (16.7%) compared to patients with normal TC levels (2.2%) at diagnosis (P = 0.0074). In conclusion, dyslipidemic changes were present prior to ALL-therapy in children with ALL but did not seem to affect dysmetabolic traits during therapy and were not predictive of on-therapy toxicities apart from an association between dyscholesterolemia at time of ALL-diagnosis and risk of thromboembolism. However, the latter should be interpreted with caution due to low number in the groups.
- 6 April 2020
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 15 (4) , e0231209
Open AccessDyslipidemia at diagnosis of childhood acute lymphoblastic leukemia
As survival of acute lymphoblastic leukemia (ALL) exceeds 90%, limiting therapy-related toxicity has become a key challenge. Cardio-metabolic dysfunction is a challenge during and after childhood ALL therapy. In a single center study, we measured triglycerides (TG), total cholesterol (TC), high (HDL) and low density lipoproteins (LDL) levels at diagnosis and assessed the association with BMI, early therapy response, on-therapy hyperlipidemia and the toxicities; thromboembolism, osteonecrosis and pancreatitis. We included 127 children (1.0–17.9 years) all treated according to the NOPHO ALL2008 protocol. Dyslipidemia was identified at ALL-diagnosis in 99% of the patients, dominated by reduced HDL levels (98%) and mild hypertriglyceridemia (61%). Hypertriglyceridemia was not associated with body mass index (P = 0.71). Five percent of patients had mild hypercholesterolemia, 14% had mild hypocholesterolemia, 13% had decreased and 1% elevated LDL-levels. Increased TG and TC levels at ALL-diagnosis were not associated with any on-therapy lipid levels. Lipid levels and BMI were not associated to MRD after induction therapy; However, BMI and hypercholesterolemia were associated with worse risk group stratification (P<0.045 for all). The cumulative incidence of thromboembolism was increased both for patients with hypo- (20.0%) and hypercholesterolemia (16.7%) compared to patients with normal TC levels (2.2%) at diagnosis (P = 0.0074). In conclusion, dyslipidemic changes were present prior to ALL-therapy in children with ALL but did not seem to affect dysmetabolic traits during therapy and were not predictive of on-therapy toxicities apart from an association between dyscholesterolemia at time of ALL-diagnosis and risk of thromboembolism. However, the latter should be interpreted with caution due to low number in the groups.
- 14 September 2018
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 66 (1) , e27437
Insulin‐dependent diabetes: A chronic complication to acute pancreatitis in childhood acute lymphoblastic leukemia
Pancreatitis is a frequent toxicity to acute lymphoblastic leukemia (ALL) treatment, significantly associated with asparaginase use, and may be followed by severe complications such as acute hyperglycaemia, need for mechanical ventilation, pseudocysts, and death. Here, we provide novel data on seven patients diagnosed with diabetes after pancreatitis and still requiring insulin treatment after a median follow‐up of 4.2 years (range: 1.7–9.2). We describe the clinical course of pancreatitis and illustrate the association between pancreatic pseudocysts, older age, and development of insulin‐dependent diabetes. Together, this study documents the persisting burden of pancreatitis in childhood ALL and underlines the need for plasma glucose level monitoring.
- 14 September 2018
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 66 (1) , e27437
Insulin‐dependent diabetes: A chronic complication to acute pancreatitis in childhood acute lymphoblastic leukemia
Pancreatitis is a frequent toxicity to acute lymphoblastic leukemia (ALL) treatment, significantly associated with asparaginase use, and may be followed by severe complications such as acute hyperglycaemia, need for mechanical ventilation, pseudocysts, and death. Here, we provide novel data on seven patients diagnosed with diabetes after pancreatitis and still requiring insulin treatment after a median follow‐up of 4.2 years (range: 1.7–9.2). We describe the clinical course of pancreatitis and illustrate the association between pancreatic pseudocysts, older age, and development of insulin‐dependent diabetes. Together, this study documents the persisting burden of pancreatitis in childhood ALL and underlines the need for plasma glucose level monitoring.
- 18 April 2018
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 65 (8) , e27071
Association between body mass index and pancreatitis in children with acute lymphoblastic leukemia
- 18 April 2018
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 65 (8) , e27071
Association between body mass index and pancreatitis in children with acute lymphoblastic leukemia